BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
More News related to BPAX
- BioSante Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
- BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
- BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Phillip B. Donenberg, its CFO, will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel(R) (testosterone gel) update at Merriman Curhan Ford's 6th Annual Investor Summit today, Tuesday November 10, 2009 at the Hotel Sofitel in New York City. Mr. Donenberg will present at 12:40 pm local time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook(TM)), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies and other newly acquired technologies. Additional information is available online at: www.biosantepharma.com.
Source: BioSante Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
